On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.

On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.